Aug. 28, 2024 — More than two decades ago, a research team discovered a type of T cell in humans that suppresses the immune system ... Sclerosis Appears to Protect Against Alzheimer's Disease ...
It also develops therapies for various neurological diseases such as amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury and chemotherapy-induced peripheral neuropathy. Nura Bio ...
(AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central ...
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders FILE - The Johnson & Johnson headquarters in New Brunswick, New Jersey, on Feb. 8, 2024.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative and multisystemic disease that limits the quality of life and survival of affected patients. Weight loss, malnutrition, and severe dysphagia ...
Here, the authors develop a high-fidelity RNA-targeting CRISPR system to suppress the repeat RNA expressed from the C9ORF72 gene, which improved abnormalities in a mouse model. CRISPR-CasRx ...
Introduction: T regulatory cells (Tregs) inversely correlate with disease progression in Amyotrophic Lateral Sclerosis (ALS ... were analyzed in plasma by Ella Automated Immunoassay System (Simple ...
Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral ...